Teplizumab: First Approval

被引：18
|
作者：
Keam, Susan J. [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2023年 / 83卷 / 05期
关键词：
C-PEPTIDE RESPONSES; TYPE-1; ANTIBODY; TRIAL;
D O I：
10.1007/s40265-023-01847-y
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Teplizumab (teplizumab-mzwv; TZIELD (TM)) is a CD3-directed monoclonal antibody (humanized IgG1 kappa) that is being developed by Provention Bio, Inc. for the treatment of type 1 diabetes (T1D). In November 2022, teplizumab was approved in the USA to delay the onset of Stage 3 T1D in adults and pediatric patients 8 years of age and older with Stage 2 T1D, based on results of a clinical trial in high-risk relatives of individuals with T1D. This article summarizes the milestones in the development of teplizumab leading to this first approval in the treatment of T1D.
引用
收藏
页码：439 / 445
页数：7
相关论文
共 50 条
  • [41] Lonapegsomatropin: Pediatric First Approval
    Lamb, Yvette N.
    PEDIATRIC DRUGS, 2022, 24 (01) : 83 - 90
  • [42] Disitamab Vedotin: First Approval
    Deeks, Emma D.
    DRUGS, 2021, 81 (16) : 1929 - 1935
  • [43] Teplizumab Therapy to Delay the Onset of Type 1 Diabetes
    Novograd, Joel
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2024, 32 (06) : 572 - 576
  • [44] Remogliflozin Etabonate: First Global Approval
    Markham, Anthony
    DRUGS, 2019, 79 (10) : 1157 - 1161
  • [45] Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes
    Ramos, Eleanor L.
    Dayan, Colin M.
    Chatenoud, Lucienne
    Sumnik, Zdenek
    Simmons, Kimber M.
    Szypowska, Agnieszka
    Gitelman, Stephen E.
    Knecht, Laura A.
    Niemoeller, Elisabeth
    Tian, Wei
    Herold, Kevan C.
    PROTECT Study Investigators
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (23) : 2151 - 2161
  • [46] FDA's Approval of the First Biosimilar to Bevacizumab
    Casak, Sandra J.
    Lemery, Steven J.
    Chung, Jee
    Fuchs, Chana
    Schrieber, Sarah J.
    Chow, Edwin C. Y.
    Yuan, Weishi
    Rodriguez, Lisa
    Gwise, Thomas
    Rowzee, Anne
    Lim, Sue
    Keegan, Patricia
    McKee, Amy E.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4365 - 4370
  • [47] Teplizumab therapy for type 1 diabetes
    Masharani, Umesh B.
    Becker, Joseph
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (03) : 459 - 465
  • [48] Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
    Keam, Susan J.
    MOLECULAR DIAGNOSIS & THERAPY, 2022, 26 (04) : 467 - 475
  • [49] Teplizumab: type 1 diabetes mellitus preventable?
    Misra, Saurav
    Shukla, Ajay Kumar
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (05) : 609 - 616
  • [50] US authorities recommend first approval of cannabis derived drug
    Dyer, Owen
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 361
12345